Eucalyptus

Metadata

Approved Indications

German Commission E

• Internal: Catarrhs of the respiratory tract
• External: Rheumatic complaints
• Noted activities: Secretomotory, expectorant, mildly antispasmodic, mild local hyperemic

ESCOP

• Internal: Supportive treatment of chronic respiratory complaints, bronchitis and bronchial asthma; symptomatic treatment of catarrhs of the upper airways
• External: Colds and rheumatic complaints

EMA/HMPC

• Well-established use: Cough associated with cold (oral, inhalation)
• Traditional use: Relief of symptoms of cold and cough; muscular pain relief (topical)
• Also recognized for use in bath additives and inhalation preparations

Agreement/Disagreement Between Bodies

Good agreement. All bodies approve internal use for respiratory catarrh. ESCOP is notably broader, including supportive treatment of bronchial asthma and chronic respiratory complaints. The EMA monograph differentiates between well-established and traditional use more carefully.

Conditions Treated

• Catarrh of the upper and lower respiratory tract (primary)
• Acute bronchitis
• Chronic bronchitis/COPD (adjunctive)
• Sinusitis/rhinosinusitis (especially isolated 1,8-cineole)
• Bronchial asthma (adjunctive, steroid-sparing)
• Common cold symptoms
• Rheumatic complaints (external use)

Mechanism of Action

1. Mucolytic/Secretolytic

• Reduces mucus viscosity and enhances mucociliary clearance
• Stimulates serous cell secretion in bronchial glands
• Comparable mucolytic potency to N-acetylcysteine (NAC) in vitro studies

2. Anti-inflammatory

• Inhibits NF-kB pathway: Suppresses nuclear translocation of NF-kB
• Inhibits arachidonic acid metabolism: Blocks 5-lipoxygenase (5-LOX) activity, reducing leukotriene synthesis
• Suppresses TNF-alpha, IL-1beta, and other pro-inflammatory cytokines
• Modulates pattern recognition receptors TREM-1 and NLRP3
• Upregulates MAP kinase phosphatase MKP-1 (anti-inflammatory regulator)

3. Bronchospasmolytic

• Mild relaxation of bronchial smooth muscle
• Mechanism partially mediated through calcium channel effects

4. Antimicrobial

• Broad-spectrum antibacterial activity in vitro
• Antiviral properties (modest)
• Biofilm disruption potential

5. Steroid-Sparing (Cineole-Specific)

• In COPD and asthma patients, cineole supplementation enables reduction of corticosteroid dosage
• Enhances glucocorticoid receptor sensitivity in vitro

Key distinction: Isolated 1,8-cineole has more targeted and better-documented pharmacology than the complex eucalyptus essential oil mixture, though the oil also contains other active terpenes (alpha-pinene, limonene, p-cymene).

Clinical Evidence Summary

Sinusitis/Rhinosinusitis

Kehrl et al. (2004) — Cineole vs. Placebo in Acute Sinusitis

• Design: Placebo-controlled, double-blind
• Intervention: 2 x 100 mg cineole capsules, 3 times daily for 7 days (total 600 mg/day)
• Result: Significant reduction in mean symptoms sum-score after 4 and 7 days
• Improvement in headache as secondary endpoint

Acute Bronchitis

Fischer & Dethlefsen (2013) — Cineole in Acute Bronchitis

• Design: Placebo-controlled, double-blind
• Intervention: 3 x 200 mg cineole daily for 10 days
• Result: Significant improvement in cough frequency and bronchitis symptoms vs. placebo
• [Source: PMC 3842692]

COPD

Worth et al. (2009) — Cineole as Adjunctive Therapy in COPD

• Design: Placebo-controlled, double-blind
• Intervention: 3 x 200 mg cineole daily as add-on to standard therapy
• Result: Significant reduction in exacerbation frequency
• Improvement in lung function parameters and quality of life

Asthma

Juergens et al. (2003) — Cineole in Bronchial Asthma

• Design: Double-blind, placebo-controlled
• Intervention: 200 mg cineole 3 times daily
• Result: Enabled significant reduction in oral corticosteroid dosage (steroid-sparing effect)
• Anti-inflammatory mechanism: Inhibition of arachidonic acid metabolism and cytokine production
• [Source: Respiratory Medicine, 97(3):250-256]

Common Cold

Exploratory Trial (2024)

• Cineole treatment (3 x 200 mg daily) reduced common cold duration
• Earlier treatment initiation correlated with better outcomes
• [Source: PMC 10795983]

Evidence Limitations

• Many trials are relatively small (n < 200)
• Most evidence is for isolated 1,8-cineole rather than whole eucalyptus oil
• Long-term data primarily from COPD adjunctive use studies
• Dose-response relationships not fully characterized

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Hypersensitivity to eucalyptus oil or cineole
• Inflammatory diseases of the GI tract and bile ducts
• Severe liver disease
• Children under 2 years: Eucalyptus oil preparations must NOT be applied to the face (especially nose area) due to risk of reflex laryngospasm and respiratory arrest (Kratschmer reflex)

Drug Interactions

• Potential to induce CYP enzymes (theoretical); may affect metabolism of other medications
• May enhance the effect of other expectorants/mucolytics
• [NEEDS-RESEARCH: Formal drug interaction studies with cineole are limited]

Side Effects

• Gastrointestinal: Nausea, vomiting, diarrhea (uncommon with oral capsules)
• Allergic: Rare skin reactions; contact dermatitis with topical use
• Respiratory: Bronchospasm in sensitive individuals (paradoxical, rare)
• Central nervous: Drowsiness at high doses (rare)

Pregnancy and Lactation

• Pregnancy: Not recommended during pregnancy due to insufficient safety data (per EMA)
• Lactation: Not recommended; volatile compounds may pass into breast milk
• No teratogenic effects reported, but precautionary avoidance is standard guidance

Toxicity Concerns

• Eucalyptus oil has a narrow therapeutic index when ingested as pure essential oil
• Lethal dose in adults estimated at 30 mL of pure oil
• Standardized capsule formulations (200 mg cineole) have wide safety margins
• Accidental ingestion of large quantities of essential oil is a pediatric poisoning risk

Clinical Dosage

1,8-Cineole Capsules (Soledum)

Eucalyptus Oil (Inhalation)

• Steam inhalation: 3-6 drops in hot water, inhale for 10-15 minutes
• 2-3 times daily for acute symptoms

Eucalyptus Oil (Internal)

• Per Commission E: Average daily dose 0.3-0.6 g essential oil (internal)
• Enteric-coated capsules preferred to avoid GI irritation

Eucalyptus Oil (External)

• Chest rub: 5-20% oil in carrier, applied to chest area
• Bath additive: Several drops in warm bath water

Sources

• German Commission E Monograph: Eucalypti aetheroleum
• ESCOP Monograph: Eucalypti aetheroleum
• EMA/HMPC Assessment Report on Eucalyptus globulus
• Juergens et al. (2003). Respiratory Medicine, 97(3):250-256.
• Fischer & Dethlefsen (2013). PMC 3842692.
• Kehrl et al. (2004). Laryngoscope, 114(4):738-742.
• Worth et al. (2009). Respiratory Research.
• Altmeyers Encyclopedia: Eucalypti aetheroleum entry.
• Sadlon & Lamson (2010). Alternative Medicine Review.
• PMC 10795983: Cineole and common cold (2024).

Connections

• Closely related to Myrtol Standardized (ELOM-080 contains 1,8-cineole as a key component)
• Compare anti-inflammatory mechanism with Pelargonium Sidoides
• Compare mucolytic action with Ivy Leaf and Marshmallow